p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP
Summary: Aerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy. Here, we report that the human carboxymethylenebutenolidase homolog (carboxymethylenebutenolidase-like [CMBL]) acts as a tumor suppressor by reprogramming glycolysis in colorectal cancer (CRC). The...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Cell Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124723014389 |
| _version_ | 1827630357734752256 |
|---|---|
| author | Yingdan Huang Chen Xiong Chunmeng Wang Jun Deng Zhixiang Zuo Huijing Wu Jianping Xiong Xiaohua Wu Hua Lu Qian Hao Xiang Zhou |
| author_facet | Yingdan Huang Chen Xiong Chunmeng Wang Jun Deng Zhixiang Zuo Huijing Wu Jianping Xiong Xiaohua Wu Hua Lu Qian Hao Xiang Zhou |
| author_sort | Yingdan Huang |
| collection | DOAJ |
| description | Summary: Aerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy. Here, we report that the human carboxymethylenebutenolidase homolog (carboxymethylenebutenolidase-like [CMBL]) acts as a tumor suppressor by reprogramming glycolysis in colorectal cancer (CRC). The anti-cancer action of CMBL is mediated through its interactions with the E3 ubiquitin ligase TRIM25 and the glycolytic enzyme phosphofructokinase-1 platelet type (PFKP). Ectopic CMBL enhances TRIM25 binding to PFKP, leading to the ubiquitination and proteasomal degradation of PFKP. Interestingly, CMBL is transcriptionally activated by p53 in response to genotoxic stress, and p53 activation represses glycolysis by promoting PFKP degradation. Remarkably, CMBL deficiency, which impairs p53’s ability to inhibit glycolysis, makes tumors more sensitive to a combination therapy involving the glycolysis inhibitor 2-deoxyglucose. Taken together, our study demonstrates that CMBL suppresses CRC growth by inhibiting glycolysis and suggests a potential combination strategy for the treatment of CMBL-deficient CRC. |
| first_indexed | 2024-03-09T14:04:40Z |
| format | Article |
| id | doaj.art-469e3a200c524b5bbef8ac571d7a8212 |
| institution | Directory Open Access Journal |
| issn | 2211-1247 |
| language | English |
| last_indexed | 2024-03-09T14:04:40Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Reports |
| spelling | doaj.art-469e3a200c524b5bbef8ac571d7a82122023-11-30T05:07:13ZengElsevierCell Reports2211-12472023-11-014211113426p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKPYingdan Huang0Chen Xiong1Chunmeng Wang2Jun Deng3Zhixiang Zuo4Huijing Wu5Jianping Xiong6Xiaohua Wu7Hua Lu8Qian Hao9Xiang Zhou10Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Lymphoma Medicine (Breast Cancer & Soft Tissue Tumor Medicine), Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, ChinaFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, ChinaState Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University, Guangzhou 510060, ChinaDepartment of Lymphoma Medicine (Breast Cancer & Soft Tissue Tumor Medicine), Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, ChinaDepartment of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USAFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Corresponding authorFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Corresponding authorSummary: Aerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy. Here, we report that the human carboxymethylenebutenolidase homolog (carboxymethylenebutenolidase-like [CMBL]) acts as a tumor suppressor by reprogramming glycolysis in colorectal cancer (CRC). The anti-cancer action of CMBL is mediated through its interactions with the E3 ubiquitin ligase TRIM25 and the glycolytic enzyme phosphofructokinase-1 platelet type (PFKP). Ectopic CMBL enhances TRIM25 binding to PFKP, leading to the ubiquitination and proteasomal degradation of PFKP. Interestingly, CMBL is transcriptionally activated by p53 in response to genotoxic stress, and p53 activation represses glycolysis by promoting PFKP degradation. Remarkably, CMBL deficiency, which impairs p53’s ability to inhibit glycolysis, makes tumors more sensitive to a combination therapy involving the glycolysis inhibitor 2-deoxyglucose. Taken together, our study demonstrates that CMBL suppresses CRC growth by inhibiting glycolysis and suggests a potential combination strategy for the treatment of CMBL-deficient CRC.http://www.sciencedirect.com/science/article/pii/S2211124723014389CP: CancerCP: Metabolism |
| spellingShingle | Yingdan Huang Chen Xiong Chunmeng Wang Jun Deng Zhixiang Zuo Huijing Wu Jianping Xiong Xiaohua Wu Hua Lu Qian Hao Xiang Zhou p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP Cell Reports CP: Cancer CP: Metabolism |
| title | p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP |
| title_full | p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP |
| title_fullStr | p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP |
| title_full_unstemmed | p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP |
| title_short | p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP |
| title_sort | p53 responsive cmbl reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase pfkp |
| topic | CP: Cancer CP: Metabolism |
| url | http://www.sciencedirect.com/science/article/pii/S2211124723014389 |
| work_keys_str_mv | AT yingdanhuang p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT chenxiong p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT chunmengwang p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT jundeng p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT zhixiangzuo p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT huijingwu p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT jianpingxiong p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT xiaohuawu p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT hualu p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT qianhao p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp AT xiangzhou p53responsivecmblreprogramsglucosemetabolismandsuppressescancerdevelopmentbydestabilizingphosphofructokinasepfkp |